

For Internal Use Only
Sec File No. 9-

Submit 1 Original
and 9 copies

OMB APPROVAL
OMB Number: 3235-0504
Expires July 31, 2004
Estimated average burden
hours per response . . . 2.00

91-1436



06060608

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 19b-4(e)

SEP 28 2006
DIVISION OF MARKET REGULATION
SECURITIES AND EXCHANGE COMMISSION

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

- Name of Self-Regulatory Organization Listing New Derivative Securities Product:
International Securities Exchange, LLC
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
iShares Trust
- Class of New Derivative Securities Product:
Investment Company Unit
- Name of Underlying Instrument:
iShares Nasdaq Biotechnology Index Fund, iShares Dow Jones U.S. Real Estate Index Fund
- If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-based:
The indexes referred to in Item 4 above are sector indexes
- Ticker Symbol(s) of New Derivative Securities Product:
IBB, IYR
- Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
New York Stock Exchange, Nasdaq Global Market and American Stock Exchange
- Settlement Methodology of New Derivative Securities Product:
Not Applicable
- Position Limits of New Derivative Securities Product (if applicable):
Not Applicable

PROCESSED

MAR 28 2007

THOMSON
FINANCIAL

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: **Michael J. Simon**

Title: **General Counsel and Secretary**

Telephone Number: **212-897-0230**

Manual Signature of Official Responsible for Form: *[Signature]*

Date: **September 27, 2006**

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	September 28, 2006



INTERNATIONAL SECURITIES EXCHANGE.

60 Broad Street New York, NY 10004
TEL: 212 943-2400
FAX: 212 425-4926
www.iseoptions.com

September 27, 2006

By Facsimile and Overnight Courier

Gail S. Jackson
Paralegal Specialist
US Securities and Exchange Commission
Division of Market Regulation
100 F Street, NE – Room 6628
Washington, DC 20549

SECURITIES AND EXCHANGE COMMISSION
RECEIVED
SEP 28 2006
DIVISION OF MARKET REGULATION

Re: Form 19b-4(e) iShares Nasdaq Biotechnology Index Fund and iShares Dow Jones U.S. Real Estate Index Fund

Dear Ms. Jackson:

The International Securities Exchange, LLC hereby files Form 19b-4(e), with respect to the iShares Nasdaq Biotechnology Index Fund and iShares Dow Jones U.S. Real Estate Index Fund. These securities are a broad-based indexes listed for trading pursuant to ISE Rule 2114, operative under Form PILOT.

Sincerely,

Michael J. Simon
General Counsel and Secretary

Attachment

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	September 28, 2006.

END